Last updated: September 5, 2026
The ketorolac tromethamine and phenylephrine hydrochloride combination is marketed in the United States as Omidria, an intraocular solution containing phenylephrine 1% and ketorolac 0.3%. Omeros developed the product and transferred U.S. commercial rights to Rayner Surgical in 2022. Omidria’s market position depends on ophthalmic surgery volume, hospital purchasing, reimbursement treatment, and the timing and scope of generic competition.
Omidria has a specialized value proposition in cataract and intraocular-lens replacement procedures: phenylephrine maintains pupil dilation, while ketorolac reduces postoperative ocular pain and inflammation. The product has no biosimilar risk because it is a small-molecule ophthalmic drug. Its principal commercial risks are generic entry, contracting pressure from hospitals and ambulatory surgery centers, and reduced reimbursement differentiation after changes to Medicare payment policy.
What is ketorolac tromethamine and phenylephrine hydrochloride used for?
Omidria is indicated for use during cataract surgery or intraocular lens replacement surgery to maintain pupil size by preventing intraoperative miosis and to reduce postoperative ocular pain. It is added to the irrigation solution used during the procedure rather than administered as a conventional topical eye drop after surgery.
| Product |
Active ingredients |
Strength |
Dosage form |
U.S. sponsor |
| Omidria |
Phenylephrine hydrochloride and ketorolac tromethamine |
1% / 0.3% |
Intraocular irrigation solution |
Rayner Surgical; originally Omeros |
| Phenylephrine ophthalmic products |
Phenylephrine hydrochloride |
Multiple strengths |
Topical ophthalmic solution |
Multiple manufacturers |
| Ketorolac ophthalmic products |
Ketorolac tromethamine |
Multiple strengths |
Topical ophthalmic solution |
Multiple manufacturers |
Omidria’s combination format distinguishes it from separately administered phenylephrine and ketorolac products. The product is used in a controlled surgical setting, which supports standardized dosing and reduces reliance on postoperative patient administration.
What FDA regulatory status does Omidria have?
The FDA approved Omidria under New Drug Application 204206 in 2014. The approval covered use during cataract surgery or intraocular lens replacement surgery. The product is a small-molecule drug and is not regulated as a biologic under the Public Health Service Act. FDA approval does not prevent an abbreviated new drug application applicant from pursuing a generic version once applicable patents and regulatory exclusivities no longer block approval.
Omidria’s commercial history also reflects a significant reimbursement event. From 2018 through 2022, the product received separate Medicare payment treatment under a temporary pass-through mechanism for certain outpatient procedures. That payment treatment reduced the pressure on hospitals and ambulatory surgery centers to absorb the product’s cost within a bundled surgical payment.
The pass-through period ended in 2022. The change increased the importance of hospital contracts, procedural economics, formulary positioning, and product price.
When does Omidria lose exclusivity?
Omidria’s market exclusivity is principally patent-driven. The active ingredients, phenylephrine and ketorolac, were established pharmaceutical ingredients before Omidria’s approval. The commercial protection therefore comes from the specific combination, formulation, manufacturing, and use claims rather than from broad exclusivity over either active ingredient.
Public FDA Orange Book records identify patents associated with Omidria. Patent term dates can be affected by patent-term adjustment, patent-term extension, terminal disclaimers, pediatric exclusivity, and post-grant events. The principal patent family has been associated with protection extending into the early 2030s.
| Protection category |
Relevance to Omidria |
Commercial effect |
| Active-ingredient patents |
Phenylephrine and ketorolac are longstanding ingredients |
Limited protection for the combination |
| Combination and formulation patents |
Cover the intraocular composition and use |
Main branded-product barrier |
| Method-of-use patents |
Cover maintaining pupil size and reducing postoperative pain during surgery |
May support litigation against certain ANDA labels |
| FDA regulatory exclusivity |
No conventional biologic exclusivity applies |
Patent position is more important than biologic exclusivity |
| Pediatric exclusivity |
Requires confirmation from current FDA records |
Could add six months to eligible patent or exclusivity periods |
The most important legal question is not whether phenylephrine or ketorolac is old. It is whether a generic applicant can obtain approval for a formulation and surgical use that avoids the enforceable claims covering the Omidria product.
What patents protect ketorolac tromethamine and phenylephrine hydrochloride?
The relevant Omidria patent estate has included U.S. patents covering intraocular compositions that combine phenylephrine and ketorolac and their use during ophthalmic surgery. Publicly associated U.S. patent numbers include U.S. Patent No. 8,754,131 and U.S. Patent No. 9,763,851, although current Orange Book records and the USPTO patent file control the operative listing, expiration, and legal status.
The estate is narrower than a conventional drug franchise patent estate because:
- The active ingredients are off-patent.
- The product is a defined combination delivered in an irrigation solution.
- Generic applicants may challenge individual formulation or method claims.
- A non-infringing generic could seek approval with a different label, concentration, manufacturing process, or use limitation.
How strong is the patent estate for Omidria?
The estate is commercially meaningful but not impregnable.
Its strengths are the product’s specific combination, specialized intraoperative use, and limited number of direct substitutes that replicate the same workflow. A generic developer would need to address not only chemical equivalence but also the regulatory and litigation consequences of using the same surgical indications.
Its weaknesses are the age of the active ingredients, the narrowness of combination claims, and the ability of ANDA applicants to contest patent validity or assert non-infringement. Formulation patents can be vulnerable to obviousness arguments when the components and their ophthalmic use are individually well known.
The product’s litigation value also depends on whether listed patents remain active, whether they are correctly listed for the approved labeling, and whether a Paragraph IV certification is filed.
Are there Paragraph IV challenges to Omidria?
A Paragraph IV certification is the standard mechanism by which an ANDA applicant asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The ANDA applicant must provide notice to the patent holder and NDA holder. The filing of a patent-infringement action within the statutory period can trigger a 30-month stay of FDA approval, subject to statutory exceptions.
Publicly available company disclosures have not established a broad, high-profile generic litigation campaign comparable with major oral drugs. The absence of a widely publicized case does not eliminate Paragraph IV risk. Generic applicants can pursue several routes:
- File a Paragraph IV certification against listed patents.
- File a Section viii statement carving out a patented method of use.
- Pursue a formulation that differs from the branded product.
- Wait for patent expiry and file with a Paragraph III certification.
- Challenge patent listing or claim scope in subsequent litigation.
The practical risk is highest if a major ophthalmic generic manufacturer determines that expected procedure volume justifies formulation development, FDA filing costs, and litigation expense.
What formulations are protected by Omidria?
Omidria’s commercial differentiation comes from its intraocular formulation. The product combines a mydriatic agent, phenylephrine, with a nonsteroidal anti-inflammatory drug, ketorolac, in a solution used during surgery.
Relevant formulation issues include:
- Concentration of each active ingredient.
- pH and osmolality.
- Sterility and preservative status.
- Compatibility with ophthalmic irrigation systems.
- Stability after dilution or admixture.
- Container-closure integrity.
- Manufacturing controls for a sterile intraocular product.
- Labeling for intraoperative use.
A generic product must meet FDA requirements for pharmaceutical equivalence and bioequivalence or another accepted pathway. For a locally delivered ophthalmic product, the regulatory burden can be more complex than for a conventional oral tablet because formulation differences can affect ocular tolerability, sterility, delivery, and clinical performance.
What is the Orange Book status of Omidria?
Omidria is listed in the FDA Orange Book as a prescription ophthalmic product with associated patent information. The Orange Book is the key public source for approved application data, therapeutic-equivalence evaluations, and patent listings.
The commercial implications are:
- A listed patent may delay approval of an ANDA if the patent holder sues after a Paragraph IV notice.
- A method-of-use patent may be addressed through a Section viii carve-out.
- A formulation patent may be more difficult to avoid if the generic seeks the same concentration and dosage form.
- Patent expiration does not guarantee immediate generic launch because FDA review, manufacturing readiness, litigation, and commercial planning remain separate events.
The current Orange Book entry should be used for operative patent status, because patent listings and expiration dates can change after regulatory or judicial events. [1]
How did Omidria revenue develop?
Omidria revenue was highly sensitive to Medicare reimbursement policy. Omeros reported strong commercial growth after the product received separate payment treatment for eligible procedures. Public company filings reported annual Omidria net sales in the approximate range of $50 million to $60 million in the period before the commercial-rights transfer, with year-to-year variation driven by reimbursement and procedure volume. [2]
The financial trajectory can be divided into four phases:
| Period |
Market condition |
Financial effect |
| 2014-2017 |
Initial launch and surgeon adoption |
Gradual penetration of cataract and lens-replacement procedures |
| 2018-2021 |
Separate Medicare pass-through payment |
Improved hospital economics and stronger sales growth |
| 2022 |
Pass-through transition and rights transaction |
Greater uncertainty around net pricing and channel economics |
| 2023 onward |
Rayner commercial ownership in the U.S. |
Product remains commercially active, but standalone U.S. sales are not publicly detailed by a public issuer |
Omeros announced an agreement under which Rayner acquired U.S. commercial rights to Omidria. The transaction provided Omeros with upfront proceeds and shifted commercialization costs and operating responsibility to Rayner. Rayner is privately held, so it does not provide the same level of product-by-product revenue disclosure as a public pharmaceutical company.
This creates an important analytical limitation: post-transfer Omidria revenue, gross margin, prescription or procedure volume, and net price cannot be reconstructed reliably from Rayner’s public disclosures. Omeros’ post-transaction financial statements may include royalties, milestone receipts, or other licensing income, but those figures should not be treated as U.S. Omidria product sales.
What licensing deal affected Omidria?
The principal commercial transaction was Omeros’ transfer of U.S. commercial rights to Rayner Surgical Group. Omeros retained an economic interest through the transaction structure, while Rayner assumed the role of commercial operator in the United States.
The deal changed the asset from an internally commercialized product into a partnered ophthalmology franchise. Its value to Omeros shifted from direct product revenue toward transaction proceeds and continuing economics. For Rayner, the transaction provided access to an approved surgical ophthalmology product with established surgeon awareness and an existing reimbursement history.
The deal’s value depends on:
- Omidria’s procedure volume.
- Net realized price after hospital discounts.
- The rate of generic entry.
- Rayner’s ability to defend or extend adoption.
- Manufacturing and supply costs.
- Reimbursement treatment in hospital outpatient settings.
What generic entry risks exist for Omidria?
Generic entry is possible but may require more than a simple low-cost copy. The principal barriers are:
Regulatory barriers
The product is sterile, intraocular, and used in surgery. Generic manufacturers must establish appropriate pharmaceutical equivalence, quality, sterility, container performance, and manufacturing controls.
Patent barriers
The applicant must address listed patents through Paragraph III, Paragraph IV, or Section viii certification. Patent litigation could delay approval even if the generic is ultimately successful.
Commercial barriers
Omidria is used in a procedural setting where reliability and surgeon preference matter. Hospitals may resist switching a surgical irrigation product if the branded product has established supply performance and clinical familiarity.
Economic barriers
The market is narrower than the market for common topical ophthalmic drugs. A generic manufacturer must achieve sufficient procedure volume to recover development, regulatory, manufacturing, and litigation costs.
Generic entry would likely produce a rapid net-price decline if multiple suppliers enter. A single first entrant could preserve some price discipline, while two or more approved suppliers could create hospital tendering and substantial discounting.
Which companies could challenge the Omidria franchise?
Potential challengers include established generic ophthalmic manufacturers and specialty pharmaceutical companies with sterile ophthalmic manufacturing capability. The commercially relevant capability is not simply ownership of ketorolac or phenylephrine products. It includes:
- FDA-compliant sterile ophthalmic production.
- Access to ophthalmic contract manufacturing.
- Ability to support ANDA litigation.
- Hospital and ambulatory surgery center distribution.
- Existing relationships with ophthalmologists and surgical centers.
Potential competitive substitutes also include separate phenylephrine and ketorolac products, compounded intraoperative mixtures, and alternative surgical protocols. These alternatives may compete on price but do not necessarily provide the same single-product workflow or branded supply assurance.
How does Omidria compare with separate phenylephrine and ketorolac products?
| Factor |
Omidria |
Separate products |
| Administration |
One intraoperative combination product |
Multiple products or preparation steps |
| Workflow |
Standardized surgical irrigation use |
More handling and dosing coordination |
| Pricing |
Branded combination premium |
Often lower ingredient cost |
| Reimbursement |
Historically benefited from separate payment policy |
Economics depend on product and procedure |
| Patent protection |
Combination and formulation claims |
Many component products are generic |
| Substitution risk |
Moderate from generic combination and alternatives |
High price pressure from established generics |
Omidria’s defense is operational convenience and standardized delivery. Its vulnerability is that hospitals may prioritize lowest total procedural cost once reimbursement no longer separately supports the branded product.
What is the revenue exposure to generic entry?
The direct revenue exposure is concentrated in Rayner’s U.S. Omidria business and Omeros’ continuing economic rights. The product’s historical annual sales in the tens of millions of dollars make it material for a specialty company but small relative to major pharmaceutical franchises.
A generic launch could affect value through four channels:
- Volume loss as hospitals convert to lower-cost products.
- Net-price erosion from contracting.
- Royalty compression under transaction agreements.
- Higher commercial spending required to retain surgical accounts.
The effect would be less severe if Rayner maintains a differentiated supply, service, or clinical position and if only one generic enters. The effect would be sharper if several ANDA holders launch near the same time after patent expiry or settlement.
What litigation and settlement issues matter?
The key litigation questions are whether Omidria patents are valid, whether the claims cover the proposed generic, and whether any settlement permits an agreed launch date before full patent expiry.
A settlement could include:
- A fixed generic launch date.
- An authorized-generic arrangement.
- A license limited by geography or indication.
- Supply or royalty provisions.
- Restrictions on formulation or labeling.
No broad public settlement should be assumed without a reported court filing, SEC disclosure, or FDA-related record. The commercial impact of any settlement would depend on the permitted launch date and whether the agreement allows one or several generic entrants.
What is the geographic coverage of the Omidria franchise?
The most visible commercial value has been in the United States, where FDA approval, Medicare reimbursement, and Orange Book patents directly affect market access. International opportunities depend on country-specific approvals, patent rights, surgical practice, and reimbursement.
The U.S. market is particularly important because:
- Cataract surgery volume is high.
- Medicare covers a substantial share of procedures.
- Outpatient surgical centers exert purchasing power.
- FDA-approved combination products can command a premium over compounded alternatives.
- Orange Book patents can delay ANDA competition.
International rights may have separate expiration dates and enforcement profiles. A U.S. patent position should not be treated as global protection.
What manufacturing and intellectual-property barriers remain?
The main manufacturing barrier is sterile ophthalmic production at commercial scale. The product must maintain sterility, concentration, stability, and compatibility through distribution and operating-room use.
The main intellectual-property barrier is the combination of formulation and surgical-use claims. Because the ingredients are old, the product’s defensibility depends on whether those claims withstand validity challenges and whether a generic can design around them without losing the commercial value of the product.
The manufacturing barrier is meaningful but not permanent. Established generic ophthalmic companies can overcome it through internal facilities or qualified contract manufacturers. The intellectual-property barrier is therefore likely to become the more important long-term variable.
Key Takeaways
- Ketorolac tromethamine and phenylephrine hydrochloride are marketed in the United States as Omidria for cataract and intraocular-lens replacement surgery.
- Omeros developed the product; Rayner acquired U.S. commercial rights in 2022.
- The product’s historical sales were in the tens of millions of dollars annually, supported by Medicare pass-through payment before that mechanism ended.
- The active ingredients are old, so protection depends on combination, formulation, method-of-use, and manufacturing patents.
- Omidria has no biosimilar risk because it is a small-molecule ophthalmic drug.
- Generic risk is credible but depends on sterile manufacturing capability, ANDA strategy, patent litigation, and hospital economics.
- Rayner’s private ownership limits public visibility into current U.S. net sales, margins, and procedure volume.
- A multi-generic launch would likely cause rapid price erosion; a single entrant could produce a slower decline.
- The current FDA Orange Book and USPTO records are the controlling sources for active patent listings and expiration analysis.
FAQs
Is Omidria the same as ketorolac eye drops?
No. Omidria is an intraocular irrigation solution that combines phenylephrine and ketorolac for use during surgery. Standard ketorolac eye drops are generally used topically for postoperative pain and inflammation.
Can hospitals substitute generic ketorolac and phenylephrine for Omidria?
They may use separate products or compounded preparations, subject to applicable clinical, regulatory, pharmacy, and procurement requirements. Such products may not replicate Omidria’s single-container formulation or labeling.
Does Omidria have biosimilar competition?
No. Biosimilars apply to biological products. Omidria is a sterile small-molecule ophthalmic drug, so any future competitors would generally follow a generic-drug pathway.
What would make a generic Omidria launch commercially attractive?
High cataract-surgery volume, patent clearance, reliable sterile manufacturing, hospital distribution, and the ability to win contracts after reimbursement changes would support a launch. Limited market size and litigation costs could deter smaller manufacturers.
Why did Medicare reimbursement matter so much to Omidria sales?
Separate payment reduced the extent to which hospitals had to absorb Omidria’s cost within a bundled procedure payment. After the pass-through period ended, hospitals had stronger incentives to negotiate price or use lower-cost alternatives.
References
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Omeros Corporation. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934: Form 10-K. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2014). Omidria, NDA 204206: Prescribing information and approval history. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Omeros Corporation. (2022). Omeros announces agreement with Rayner for U.S. commercial rights to Omidria. Company press release.
-
U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Public Search. https://www.uspto.gov/patents-application-process/search-patents
